The Latin America, Middle East and Africa Dementia Treatment Market would witness market growth of 10.1% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $583.6 million by 2031. The Argentina market is capturing a CAGR of 10.9% during (2024 - 2031). Additionally, The UAE market would showcase a CAGR of 9.7% during (2024 - 2031).
Beyond pharmacological advancements, medical research also explores non-drug interventions that can complement existing treatments. These include cognitive training programs, lifestyle modifications, and digital health technologies to monitor and support patients. For instance, wearable devices and mobile applications are being developed to track cognitive function, physical activity, and other health parameters, providing valuable data that can inform personalized treatment plans.
In addition to advancements in pharmaceutical treatments, non-pharmacological interventions are gaining traction in the dementia treatment market. These interventions, which include cognitive stimulation therapy, physical exercise, and occupational therapy, aim to improve cognitive function, delay the progression of symptoms, and enhance the overall well-being of individuals with dementia. Integrating these holistic approaches into dementia care plans is increasingly recognized for its potential to provide comprehensive and patient-centered care.
The demand for dementia treatment in Saudi Arabia is on the rise as a result of the country's robust medical tourism industry and the increasing prevalence of dementia. As the population ages, the Saudi Ministry of Health anticipates an increase in the number of dementia cases in Saudi Arabia. Saudi Arabia is becoming a significant player in medical tourism, drawing patients from neighbouring countries as a result of its advanced medical technologies and high-quality healthcare services.
The Saudi government has been focusing on enhancing dementia care through initiatives like the Saudi Vision 2030, which includes significant investments in healthcare infrastructure and medical research. These efforts contribute to the growing demand for effective dementia treatments in Saudi Arabia. Hence, these factors are likely to create significant opportunities for growth and investment in the dementia treatment market in LAMEA.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Dementia Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $583.6 million by 2031. The Argentina market is capturing a CAGR of 10.9% during (2024 - 2031). Additionally, The UAE market would showcase a CAGR of 9.7% during (2024 - 2031).
Beyond pharmacological advancements, medical research also explores non-drug interventions that can complement existing treatments. These include cognitive training programs, lifestyle modifications, and digital health technologies to monitor and support patients. For instance, wearable devices and mobile applications are being developed to track cognitive function, physical activity, and other health parameters, providing valuable data that can inform personalized treatment plans.
In addition to advancements in pharmaceutical treatments, non-pharmacological interventions are gaining traction in the dementia treatment market. These interventions, which include cognitive stimulation therapy, physical exercise, and occupational therapy, aim to improve cognitive function, delay the progression of symptoms, and enhance the overall well-being of individuals with dementia. Integrating these holistic approaches into dementia care plans is increasingly recognized for its potential to provide comprehensive and patient-centered care.
The demand for dementia treatment in Saudi Arabia is on the rise as a result of the country's robust medical tourism industry and the increasing prevalence of dementia. As the population ages, the Saudi Ministry of Health anticipates an increase in the number of dementia cases in Saudi Arabia. Saudi Arabia is becoming a significant player in medical tourism, drawing patients from neighbouring countries as a result of its advanced medical technologies and high-quality healthcare services.
The Saudi government has been focusing on enhancing dementia care through initiatives like the Saudi Vision 2030, which includes significant investments in healthcare infrastructure and medical research. These efforts contribute to the growing demand for effective dementia treatments in Saudi Arabia. Hence, these factors are likely to create significant opportunities for growth and investment in the dementia treatment market in LAMEA.
Based on Type, the market is segmented into Diagnosis (Imaging Techniques, Cognitive Assessment Tools, Genetic Testing, Biomarker Analysis and Others) and Drugs (Cholinesterase Inhibitors, NMDA Receptor Antagonist, MAO Inhibitors, Combination Drug and Others). Based on Dementia Drugs Route of Administration, the market is segmented into Oral, Transdermal Patch, and Injectable. Based on Dementia Drugs Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Based on Indication, the market is segmented into Alzheimer’s Disease Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia (FTD), Parkinson Disease Dementia and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Eisai Co., Ltd.
- Eli Lilly And Company
- F.Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Market Report Segmentation
By Type- Diagnosis
- Imaging Techniques
- Cognitive Assessment Tools
- Genetic Testing
- Biomarker Analysis
- Others
- Drugs
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
- Oral
- Transdermal Patch
- Injectable
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson Disease Dementia
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Dementia Treatment Market by Type
Chapter 5. LAMEA Dementia Treatment Market by Dementia Drugs Route of Administration
Chapter 6. LAMEA Dementia Treatment Market by Dementia Drugs Distribution Channel
Chapter 7. LAMEA Dementia Treatment Market by Indication
Chapter 8. LAMEA Dementia Treatment Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Eisai Co., Ltd.
- Eli Lilly And Company
- F. Hoffmann-La Roche Ltd.
- Biogen, Inc.
- AbbVie, Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline PLC (GSK)
- Cipla Limited
Methodology
LOADING...
